Now's the opportunity for PBMs to really lower out of pocket shelling out and go ahead and take measures to extend access to FDA accepted biosimilars on national formularies and allow them to compete. Eventually, Opposition can be a gain-gain for the market and the client.It was also aggravating - and somewhat sketchy - to begin to see the "BBB Acc